Rules-Based Medicine Takes Over Satoris' IP in CNS Diseases
Deal includes studies on biomarkers for clinical and research use.!--h2>
Rules-Based Medicine (RBM) is buying intellectual property assets from Satoris covering studies on biomarkers and biomarker panels for clinical and research use in the areas of Alzheimer disease, frontal temporal dementia, Parkinson disease, and other conditions that affect the central nervous system.
RBM notes that its biomarker testing service provides clinical researchers, physicians, and healthcare providers with quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. Last month Myriad Genetics said it would pay $80 million to take over RBM.
Remarking on the deal with Satoris, Craig Benson, president and CEO of RBM, says, "These assets from Satoris will be an important contributor as we continue to develop research and diagnostic offerings for neurodegenerative illnesses which affect millions of individuals and families."
RBM’s Multi Analyte Profiling (MAP) technology offers preclinical and clinical researchers protein analyses in multiple species from a small sample volume. RBM’s MAP technology also supports the company’s internal efforts to develop diagnostics. The firm’s first commercial test is VeriPsych™, a blood-based tool that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers.
RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture, a fully-closed, reproducible whole blood culture system. Last week the Institut Pasteur’s research project called Milieu Interieur (or the environment within), which aims to understand the complexities of the human immune system, signed on RBM to use TruCulture.